Treatment.com AI Provides an Update on the Status of Exercised Warrants
Rhea-AI Summary
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will enable the company to expedite its plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI also has a strong acquisition pipeline under review, which could accelerate their growth strategy. The company's core product is the Global Library of Medicine (GLM), an AI-driven healthcare engine providing clinical information with >92% accuracy on first diagnosis.
Positive
- Nearly 800,000 warrants exercised, raising approximately $500,000
- Remaining warrants could potentially bring in over $2 million
- Plans to launch 'AI Patient' and 'AI Doctor in the Pocket' products in fall 2024
- Strong acquisition pipeline under review for potential accelerated growth
- Global Library of Medicine (GLM) AI engine provides >92% accuracy on first diagnosis
Negative
- None.
●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.
●Remaining warrants could bring over
●Robust acquisition pipeline
VANCOUVER, British Columbia, July 24, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024.
Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars.
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our “AI Patient” and “AI Doctor in the Pocket'' products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
If you would like to find out more about Treatment’s products and services, please email at info@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.